

## INDEX

(Page number shown is first page of article in which entry is indexed.)

- Acetaminophen, 418  
Acetanilide, 418  
Acetanilide hydroxylation, 191  
    effect of metyrapone and analogs on, 184  
Acetone, effects on electron paramagnetic resonance signals, 231  
Acetophenetidin, effect of analgesics and cigarette smoke on metabolism of, 211  
N-acetyl-*p*-aminophenol, effect of analgesics and cigarette smoke on metabolism from acetophenetidin, 211  
Active centers of hepatic microsomal cytochrome P-450, 194  
Active site of cytochrome P-450, 1  
Adjuvant-induced arthritis in rat, impaired drug metabolism in, 251  
*ah* locus, association with drug-metabolizing enzymes, 231  
Albumin, transfer from cytochrome P-420 in metabolism of cytochrome P-450, 293  
Alcohol dehydrogenase, differentiation from microsomal ethanol-oxidizing system, 428  
Alkyl hydroperoxides, 92  
Allopurinol, inhibition of drug metabolism after, 402  
Allylisopropylacetamide, 259, 286  
2-Allyl-2-isopropylacetamide, loss of cytochrome P-450 by, 267  
Amines  
    individual, N-oxidation of, 299  
    primary, deamination of, 337  
Amino acyl tRNA synthetase activity, 239  
*p*-Aminobenzoic acid, 259  
Amino carbinol oxidation, 322  
5-Aminolevulinate synthetase activity, relation of loss of heme to, 267  
Aminolevulinic acid, 259  
Aminotriazole, 259  
Amphetamine deamination, phenylacetone oxime in, 332  
Analgesics, effect on acetophenetidin metabolism, 211  
Aniline hydroxylation, 191  
Antituberculous drugs, effect on cytochrome P-450 content and hydroxylating enzyme system, 224  
Arthritis, adjuvant-induced, in rat: impaired drug metabolism in, 251  
Arylamines, N-oxidation, 314  
Aryl hydrocarbon benzo[*a*]pyrene hydroxylase, 231  
Aryl hydrocarbon hydroxylase, induction in human skin in tissue culture, 386  
Azo reduction, type II substrate oxidation and, enhancement by metyrapone, 191  
Barbiturates, breakdown of cytochrome P-450 heme by, 275  
Benzo[*a*]pyrene hydroxylation by aryl hydrocarbon hydroxylase, 386  
Benzpyrene hydroxylase, 380  
Benzpyrene metabolism in control and induced rats and mice, 380  
Biliary excretion, effects of phenobarbital in man, 424  
Bilirubin, effect of ethanol on, 428  
Blood flow, liver, to determine drug half-lives, 411  
Carbanions, formation and binding by cytochrome P-450, 176  
Carbon disulfide, loss of cytochrome P-450 by, 267  
Carbon monoxide, 191  
    binding activation energies, 1  
    binding rate constants, 1  
    effect on N-oxidation, 299  
    production, 286  
    specific carrier in lung and placenta, 374  
Carcinogen metabolism, induction in skin in tissue culture, 386  
Catabolism  
    heme, 286  
    hemoprotein, 286  
Catalase  
    differentiation from microsomal ethanol-oxidizing system, 428  
    role in hepatic microsomal ethanol oxidation, 441  
Chlorinated hydrocarbons, carbanion formation by reduction of, 176  
Cholestasis, effect of phenobarbital on, 424  
Cholesterol  
    content of lung and liver microsomes, 358  
    metabolism, effects of ethanol on, 428  
Cigarette smoke, effect on acetophenetidin metabolism, 211  
Cobaltous chloride, 259  
Cortisol, to determine drug half-lives, 411  
Cortisone acetate, effect on drug metabolism, 216  
Covalent binding, 418  
Cyanide, effects on drug oxidation, 139  
Cytochrome *b<sub>5</sub>*, 129  
    electron transfer mediated by, 150  
Cytochrome P-420  
    characterization, 45  
    differences in 'untreated and 3-methylcholanthrene-treated rats, 40  
    transfer to albumin in metabolism of cytochrome P-450, 293

- Cytochrome P-448  
 effect on substrate specificity, 29  
 extinction coefficient, 29  
 phospholipid content, 29  
 purification, 29  
 spectrum, 29
- Cytochrome P-450  
 anomalous properties, 6  
 chemistry, from endocrine systems, 21  
 destruction, drug-induced, 267  
 effect on substrate specificity, 29  
 enzyme systems, mechanism, 164  
 extinction coefficient, 29  
 free hepatic polyribosomes and, 62  
 genetic differences, 231  
 heme, breakdown by barbiturates, 275  
 hydrophobic region, 6  
 mechanism of action, 92  
 molecular function, 98  
 NADPH-cytochrome *c* reductase and, 121  
 N-oxidation of amines, 299  
 optical and magnetic probes of, 45  
 oxygenated, 129  
 partial purification, 6  
 phospholipid content, 29  
 placental, role in oxygen diffusion, 368  
 purification, 29  
 reductase, 380  
 solubilized, 156  
 spectrum, 6, 29  
 substrate complexes, 111
- Cytochrome P-450<sub>cam</sub>, 1
- DDT and benzpyrene as inducers in rats and mice, 380
- Deamination, microsomal, heavy isotope studies, 337
- Degradation of microsomal hemoproteins, 256
- Dehydrogenase, microsomal, 322
- Dehydrogenation of 2-hydroxymedazepam, 322
- Desmethylinipramine metabolism, interindividual differences, 469
- Detergent(s)  
 effects on electron paramagnetic resonance signals, 231  
 treatment of microsomes, 74
- Diazepam, from oxidation of 2-hydroxymedazepam, 322
- 3, 5-Diethoxycarbonyl-1, 4-dihydro-2, 4, 6-trimethylpyridine, 259
- Dimethylaniline, N-oxidation of, 314
- Dioxymethylene compounds as ligands for cytochrome P-450, 176
- Diphenylhydantoin metabolism, interindividual differences, 469
- Disulfiram, inhibition of drug metabolism after, 402
- L-Dopa, inhibition of drug metabolism after, 402
- DPNH synergism of TPNH-dependent mixed function oxidase reactions, 139
- Dynamic organization of endoplasmic reticulum membranes, 66
- Electron paramagnetic resonance, to probe spin state of iron, 45
- Endocrine systems, chemistry of cytochrome P-450 from, 21
- Endoplasmic reticulum, synthesis and degradation of membrane proteins in, 84
- Endoplasmic reticulum membranes, dynamic organization of, 66
- Enzyme inducers, effect on substrate specificity, 199
- Enzyme proteins, turnover in microsomal membrane, 80
- Enzyme-substrate complex, 111
- Ethanol metabolism, oxidative and peroxidative mechanisms, 449
- Ethanol oxidation  
 hepatic microsomal, role of hydrogen peroxide and catalase in, 441  
 hepatic microsomal, significance and characterization, 428  
 NADPH-cytochrome *c* reductase in, 455
- Ethylmorphine, spectral changes, 129
- Ethylmorphine N-demethylation, effect of steroids on, 216
- Extinction coefficient of cytochromes P-450 and P-448, 29
- Extrahepatic drug metabolism, effects of hepatic inducers and inhibitors on, 342
- Extrahepatic microsomal N-oxidation, 299
- Extrahepatic mono-oxygenase system, 350
- Flavoprotein-catalyzed N-oxidation, 314
- Fluorene, interaction with cytochrome P-450, 176
- Furosemide, 418
- Genetic differences in cytochrome P-450, 231
- Glucose metabolism, effects of ethanol on, 428
- Glutathione, 418
- Glycine conjugation, 259
- Heavy isotope studies of microsomal deamination, 337
- Heme catabolism, 286
- Heme oxygenase, 286
- Heme synthesis, 259
- Heme transfer, implication in metabolism of cytochrome P-450, 293
- Hemoglobin binding by lung microsomes, 358  
 emolysis, 418
- Heterogeneity of cytochrome P-450 in vicinity of heme, 45
- Hexobarbital, spectral changes, 129
- Hexobarbital hydroxylation, effect of steroids on, 216
- Hydrogen peroxide, role in hepatic microsomal ethanol oxidation, 441
- Hydroperoxides, 92
- Hydrophobic region of cytochrome P-450, 6
- Hydroxylase, microsomal, unspecific, induction in human liver, 224
- 11 $\beta$ -Hydroxylase of adrenocortical mitochondria, cytochrome P-450 function and, 21

- Hydroxylation, drug, 92  
2-Hydroxymedazepam, oxidation, 322  
Hyperlipemia from ethanol, 428
- Induction of cytochrome P-450 reductase by phenobarbital vs. 3-methylcholanthrene, 380  
Inelastic light-scattering studies of phospholipids, 74  
Inhibition of drug metabolism, 164, 402
- Inhibitors  
and inducers, liver and kidney cortex compared, 350  
effects on N-oxidation, 299  
of drug metabolism, 162
- Initiation factor activity after 3-methylcholanthrene and  $\beta$ -naphthoflavone, 239
- Interindividual differences  
in drug metabolism in man, 469  
in drug oxidation in man, 411
- Ionic strength, effects on cytochrome P-450 reductase, 380
- Isosafrole, effect on extrahepatic drug metabolism, 342
- Ligands  
carbanions as, 176  
cytochrome P-450<sub>cam</sub>, 1
- Lipid peroxidation, 286
- Lung, oxygen and carbon monoxide carrier in, 374  
Lung microsomes, relation to drug metabolism, 358
- M<sub>1</sub> factor, 239  
M<sub>3</sub> + M<sub>2</sub> factor, 239  
Magnetic probe of cytochrome P-450's, 45  
Membrane proteins, synthesis and degradation of, 84  
Membranes, enzyme turnover in, 80  
Mercaptide ligand, fixed, in oxidized hemoprotein, 45  
Messenger RNA-polyribosome-cytochrome P-450 complex, 62  
Messenger RNA's, effect of phenobarbital on, 248  
Metal ion effects on cytochrome P-450 reductase, 380  
Methanol oxidation, NADPH-cytochrome *c* reductase in, 455  
Methemoglobinemia, 418  
3-Methylcholanthrene  
effects on electron paramagnetic resonance spectra, 231  
effect on extrahepatic drug metabolism, 342  
effect on P-420 hemoproteins in rat, 40  
initiation factor after, 239
- Methylenedioxyphenyl compounds, 391  
Methyltestosterone, effect on drug metabolism, 216  
Metyrapone, 191  
determination of active centers of hepatic microsomal cytochrome P-450, 194  
modifier of microsomal drug metabolism, 184
- Mitochondrial electron transport, 139  
Mixed function oxidase activities and related enzymes, 358  
Mixed function oxidase reactions, TPNH-dependent, DPNH- synergism of, 139
- Mixed function oxidations, 129  
Molecular function of cytochrome P-450, 98  
Molecular size-turnover correlation of membrane proteins, 84  
Molecular weight of solubilized cytochrome P-450, 156  
Mononuclear ferric iron, probes of spin state in oxidized cytochrome P-450, 45  
Mono-oxygenase induction, genetic differences in cytochrome P-450 during, 231  
Mono-oxygenase system, rat kidney cortex, 350  
Mössbauer parameters of cytochrome P-450<sub>cam</sub>, 1  
Mutual depletion system kinetics, 194
- NAD<sup>+</sup>-dependent microsomal dehydrogenase, 322  
NADH oxidation, relation to NADPH oxidation, 150  
NADPH, formation of microsomal hydrogen peroxide from, 441  
NADPH-cytochrome *c* reductase, 92  
microsomal oxidation of ethanol and methanol, 455  
role in microsomal reactions, 121  
NADPH-cytochrome P-450 reductase, 92  
NADPH oxidations, relation to NADH oxidation, 150  
 $\beta$ -Naphthoflavone, initiation factor after, 239  
2-Naphthylamine, N-oxidation of, 314  
Necrosis, liver, 418  
Neoprontosil reduction, 191  
2-Nitropropane, ligand binding of, 176  
Nonmercaptide ligand, variable, in oxidized hemoprotein, 45  
Nonsubstrates, interaction with flavoprotein oxidase, 314  
Nortriptyline, inhibition of drug metabolism after, 402  
Nortriptyline metabolism, interindividual differences, 469  
Novaminsulfonum, effect on drug metabolism, 224  
N-oxidation of arylamines, 314  
N-oxidation of individual amines, cytochrome P-450 role, 299
- Optical difference spectra, 391  
Optical probe of cytochrome P-450's, 45  
Oxidative mechanisms of ethanol metabolism, 449  
Oxygen carrier, specific, in lung and placenta, 374  
Oxygen diffusion, role of placental cytochrome P-450 in, 368  
Oxygen incorporation, mechanism, 299  
Oxygen pressure, effects on N-oxidation, 299  
Oxyphenbutazone oxidation, antipyrine half-life to assess, 411
- Particle size, 74  
Peroxidative mechanisms of ethanol metabolism, 449  
pH, effect on oxidation pathways, 299  
Phenacetin, 418  
Phenacetin-caused spectral changes, 111  
Phenobarbital  
effects on biliary excretion in man, 424  
effect on extrahepatic drug metabolism, 342  
effect on messenger RNA's, 248

- Phenylacetone oxime, intermediate in amphetamine deamination, 332
- Phenylbutazone oxidation, antipyrine half-life to assess, 411
- Phospholipase C digestion, effect on lung and liver mixed function oxidase activities, 358
- Phospholipid, role in microsomal hydroxylations, 156
- Phospholipid content  
of cytochromes P-450 and P-448, 29  
of lung and liver microsomes, 358
- Phospholipid exchange in microsomal membrane, 74
- Piperonyl butoxide, 391  
effect on extrahepatic drug metabolism, 342
- Placenta, oxygen and carbon monoxide carrier in, 374
- Placental cytochrome P-450, role in oxygen diffusion, 368
- Polyribosomes, free hepatic, associated with cytochrome P-450, 62
- Polyuridylic acid-directed <sup>14</sup>C-phenylalanine incorporation, 239
- Porphyria, 259  
experimental, 286  
experimental, induced by allylisopropylacetamide and related compounds, 275
- Porphyrin, effect of ethanol on, 428
- Prazepam, inhibition of drug metabolism after, 402
- Pseudomonas putida* cytochrome P-450, 14
- Reconstituted mixed function oxidase system, 156
- Reduced pyridine nucleotides, 98
- Reticuloendothelial cells, spleen and liver, in metabolism of cytochrome P-450, 293
- Reverse type I spectral change, 111
- Rifampicin, effect on cytochrome P-450 content and hydroxylating enzyme system, 224
- RNA content of lung and liver microsomes, 358
- Sedimentation of resolved cytochrome P-450, 156
- Skin, human, aryl hydrocarbon hydroxylase induction in cultures of, 386
- Smooth endoplasmic reticulum, proliferation, 428
- Species differences in induction by DDT vs. benzpyrene, 380
- Spectral changes, 111  
in cytochrome P-450 after 3-methylcholanthrene treatment, 40
- Spirolactone, effect on drug metabolism, 216
- Stearoyl-CoA, effects on drug oxidation, 139
- Steroids, effect on rat drug metabolism, 216
- Stoichiometry of oxygen reduction, 98
- Substrate binding  
effects on electron paramagnetic resonance signals, 231  
to cytochrome P-450, effect of phospholipid on, 156
- Substrate-induced difference spectra, lung and liver, 358
- Substrate interaction, 111  
with cytochrome P-450, 98
- Substrate specificity  
effect of cytochromes P-450 and P-448 on, 29  
effect of enzyme inducers on, 199  
liver and kidney cortex compared, 350
- Superoxide, 92
- Synergists, effect on drug metabolism, 391
- Synthesis of microsomal hemoproteins, 256
- Temperature changes, effects on electron paramagnetic resonance signals, 231
- Tetrahydrocannabinol  
inhibition of drug metabolism after, 402  
metabolism in man, 461  
metabolite disposition, 461
- Toxic metabolites, 418
- TPNH-dependent mixed function oxidase reactions, DPNH synergism of, 139
- Turnover of microsomal membrane proteins, 80  
Comparison *in vivo* and *in vitro*, 87
- Type I drugs, 139
- Type II drugs, 139
- Type II substrate oxidation and azo reduction, enhancement by metyrapone, 191
- Type III difference spectrum, 391

## AUTHOR INDEX

- Alvares, A. P., 386  
Anders, M. W., 293, 642, 659  
Anderson, D. J., 691  
Arison, B. H., 721  
Aurori, K. C., 669  
Autor, A. P., 156
- Baker, R. C., 391  
Baron, J., 98, 121, 129  
Beck, F. J., 251  
Bend, J. R., 358  
Bloomfield, V. A., 74  
Blumberg, W. E., 45  
Bower, R. J., 721  
Boyer, R. F., 92  
Branch, R. A., 679, 687  
Breckenridge, A., 411  
Bresnick, E., 239  
Bridges, J. W., 342  
Brodie, B. B., 418  
Burns, B., 368, 374
- Carter, E. A., 449  
Casmer, C., 611  
Castle, M. C., 590  
Cavallito, J., 211  
Cha, Y.-N., 516  
Chabner, B. A., 580  
Chakraborty, J., 342  
Chando, T. J., 619  
Chang, R., 611  
Cinti, D. L., 111, 350, 516  
Cohen, A. I., 619  
Conney, A. H., 199, 386, 766  
Considine, N., 231  
Coon, M. J., 92, 156  
Cooper, D. Y., 21  
Cooper, M. J., 642, 659  
Correia, M. A., 139  
Cunningham, R. F., 742
- Davies, D. S., 411  
Dayton, P. G., 742  
DeCarli, L. M., 428  
Deckert, F. W., 704  
Dehlinger, P. J., 84  
De Matteis, F., 267  
Desiderio, D. M., 489  
Dewan, R. K., 74  
Di Carlo, F. J., 530  
Dice, J. F., 84  
Douglas, J. F., 737  
Drayer, D. E., 577  
Duppel, W., 156
- Edelson, J., 737  
Eisenbrandt, L. L., 523  
Ellin, Á., 350  
Erickson, R. R., 74  
Ernster, L., 66  
Estabrook, R. W., 98, 129, 350  
Evans, G. H., 679
- Farquhar, D., 580  
Fleischmann, R. A., 224  
Fouts, J. R., 380
- Gabriel, T. F., 557  
Garteiz, D. A., 565  
Gerber, N., 489  
Gillespie, D. D., 211  
Gillette, J. R., 150, 164, 216, 418  
Glazko, A. J., 711  
Gógl, A., 424  
Gottlieb, J. A., 645, 756  
Gram, T. E., 74, 358  
Griffin, B. W., 14  
Gunsalus, I. C., 1  
Gurtner, G. H., 368, 374
- Hamrick, M. E., 216  
Harvey, D. J., 569  
Hasegawa, E., 259  
Heidema, J. K., 156  
Hildebrandt, A. G., 129, 194  
Hill, R. M., 569  
Ho, D. H. W., 752  
Hodgson, E., 391  
Holtzman, J. L., 74  
Hook, G. E. R., 358  
Hopkins, R., 342  
Horning, M. G., 569  
Horváth, T., 424  
Hucker, H. B., 332, 721  
Husain, S., 523
- Ichikawa, Y., 62  
Imai, Y., 6  
Isaacson, E. L., 121  
Israili, Z. H., 742  
Isselbacher, K. J., 449
- Jacobson, M., 199, 275, 766  
Jakobsson, S. V., 350  
Jávor, T., 424  
Johns, D. G., 580  
Johnson, A. O., 669  
Jollow, D. J., 418

- Kahe, G. F., 191  
 Kappas, A., 386  
 Kaschnitz, R. M., 156  
 Khaliq, A., 756  
 Kimmel, H. B., 537  
 Knapp, W. C., 565  
 Kniffen, F., 259  
 Kohl, K. B., 455  
 Kolis, S. J., 322, 557  
 Kon, H., 231  
 Kuntzman, R., 199, 275, 766  
 Kupfer, D., 760
- Lage, G. L., 590  
 Lake, B. G., 342  
 Lan, S. J., 619  
 Lanclos, K. D., 239  
 Lee, N. W., 628  
 Leeson, G. A., 565  
 Leibman, K. C., 184, 543, 775  
 Leigh, S., 386  
 Lemberger, L., 461  
 Le Page, G. A., 756  
 Levin, W., 29, 199, 275, 386, 766  
 Lewis, D. D., 530  
 Lieber, C. S., 428  
 Lin, C., 611  
 Lipscomb, J. D., 1  
 Liu, A. L., 537  
 Loo, T. L., 580, 645  
 Lu, A. Y. H., 29, 199, 766  
 Lu, K., 645  
 Ludwig, B. J., 737
- Mailman, R. B., 391  
 Maines, M. D., 293  
 Mannering, G. J., 40, 139, 663  
 Marver, H. S., 286  
 Mason, H. S., 62  
 Mason, J. I., 98  
 Masters, B. S. S., 121, 455  
 Matsubara, T., 98  
 Matsumura, S., 248  
 McKee, E. M., 314  
 McMahon, F. G., 721  
 McMahon, R. E., 337, 628  
 Menard, R. H., 216  
 Merits, I., 691  
 Meyer, U. A., 286  
 Minck, K., 191  
 Mirkin, B. L., 659  
 Mitchell, J. R., 150, 418  
 Mitoma, C., 698  
 Moldeus, P., 111, 516
- Nebert, D. W., 231  
 Negishi, M., 80  
 Nelson, E. B., 121, 455  
 Netter, K. J., 162, 191
- Nies, A. S., 679, 687  
 Nowlin, J., 569
- Omura, T., 80, 248  
 Orme, M., 411  
 Orrenius, S., 66, 111, 350  
 Ortiz, E., 184, 543, 775
- Parke, D. V. W., 342  
 Parli, C. J., 337, 628  
 Passananti, G. T., 402  
 Peisach, J., 45  
 Perel, J. M., 742  
 Peterson, J. A., 14, 129  
 Philpot, R. M., 391  
 Pieper, W. A., 634  
 Piper, W., 259  
 Poulsen, L. L., 314
- Reidenberg, M. M., 577  
 Remmer, H., 224  
 Rhodes, R. E., 721  
 Roots, I., 194  
 Rosenfeld, J., 760  
 Rosenthal, O., 21  
 Ruelius, H. W., 537  
 Ryan, D., 29, 199
- Sasame, H. A., 150, 164  
 Satake, H., 6  
 Sato, R., 6  
 Schacter, B. A., 121, 286  
 Schenkman, J. B., 111, 350, 516  
 Schimke, R. T., 84  
 Schleyer, H., 21  
 Schmid, R., 256  
 Schnabel, K. H., 176  
 Schoene, B., 224  
 Scholz, R., 441  
 Schreiber, E. C., 619  
 Schwartz, M. A., 322, 557  
 Scott, K. N., 506  
 Segaloff, A., 537  
 Seibert, R. A., 489  
 Sernatinger, E., 275  
 Shand, D. G., 679, 687  
 Shoeman, D. W., 40  
 Sisenwine, S. F., 537  
 Sitar, D. S., 663  
 Sjöqvist, F., 469  
 Skeen, M. J., 634  
 Somogyi, A., 199  
 Sonders, R. C., 691  
 Stauffer, S. C., 721  
 Stern, J. O., 45  
 Stratton, C., 569  
 Stripp, B., 164, 216  
 Strobel, H. W., 92  
 Symchowicz, S., 611

- Takemori, A. E., 642  
Taylor, J. M., 84  
Tényi, I., 424  
Tephly, T. R., 259  
Thompson, R. M., 489  
Thor, H., 350  
Thorgeirsson, S. S., 150, 411  
Thurman, R. G., 441  
Toome, V., 557  
Trussler, P., 259
- Uehleke, H., 299  
Ullrich, V., 176  
Umbenhauer, E. R., 721
- Valerino, D. M., 669  
van der Hoeven, T. A., 156  
Vane, F. M., 40  
Vesell, E. S., 402, 669  
von Bahr, C., 469
- Waddell, W. J., 598  
Webb, C., 259  
Weiner, I. M., 742  
Welch, R. M., 211  
Weliky, I., 619  
Werringloer, J., 98  
West, S. B., 29, 199  
White, S. D., 721  
Whitehouse, M. W., 251  
Wilder, B. J., 506  
Wilkinson, G. R., 679  
Williams, C. M., 506  
Williams, T. H., 557  
Wolpert, M. K., 580  
Wosilait, W. D., 523  
Wright, G. J., 565
- Zampaglione, N. G., 216  
Ziegler, D. M., 314  
Zuleski, F. R., 530

## SUBJECT INDEX\*

- Acetanilide  
  *p*-hydroxylation, inhibition, 775  
  metabolic rate, 766  
N-Alanyldopamine-<sup>14</sup>C, metabolism, species differences, 691  
Aldehyde oxidase, synthesis and interaction of dialkyl esters with, 580  
Aminopyrine, N-demethylation, inhibition, 775  
Amobarbital, hydroxylation, 663  
Aniline, *p*-hydroxylation, inhibition, 775  
Aniline hydroxylase, effect of centrally active drugs on, 669  
Anticoagulants, metabolism, 704  
9-β-D-Arabinofuranosyladenosine, in man, 756  
1-β-D-Arabinofuranosylcytosine, O<sup>2</sup>,2'-cyclocytidine as a depot form of, 752  
9-β-D-Arabinofuranosylhypoxanthine, in man, 756  
Arabinosyl-6-mercaptopurine, metabolism and disposition, 645  
1-Arylimidazoles, as inhibitors of drug metabolism, 775  
Assay, radioactive, for hexobarbital hydroxylase in liver microsomes, 760  
  
Barbiturates, metabolism, 663  
Bile, rat, identification of metabolites in, 489  
Biliary excretion, <sup>14</sup>C-dicumarol, in rat, 523  
Blocking agent, β-receptor, in dog, 565  
Blood flow, liver, effects on propranolol disposition, 687  
Bornanediones, reduction, 543  
Borneols, stereospecific formation from D- and L-camphor, 543  
  
Camphor, reduction and hydroxylation, 543  
Cephalothin, ion-pair extraction and liquid chromatography, in man, 659  
Chlorocyclizine, N-demethylation, 766  
Chlorocyclizine-<sup>14</sup>C, distribution, in mice, 598  
2-Chloro-6-phenylphenoxyethylamine, metabolism, relationship with activity as mono-oxygenase inhibitor, 628  
Chlorpromazine, effect, on liver microsomal enzymes, 669  
5-Chlorosalicylic acid, binding and disappearance, in rat and dog, 737  
Chromatography  
  anion exchange, high pressure, 663  
  
\* The subject index for "The Second International Symposium on Microsomes and Drug Oxidations" is found in *Drug Metabolism and Disposition* 1: 483-486 (January/February), 1973. The author index for the January/February issue is included in the author index presented on p. 787.  
  
gas, analysis of permethylated rat bile by, 489  
liquid, high-speed, of cephalothin and deacetyl-  
  cephalothin, in man, 659  
Contraceptive, oral, disposition, in rat, 530  
Cuprex, toxicity, in man, 577  
Current Literature, 552, 606, 653, 715, 780  
1-(2-Cyanophenyl)imidazole, as inhibitor of drug  
  metabolism, 775  
O<sup>2</sup>,2'-Cyclocytidine, metabolism, 752  
Cytochrome P-420, extinction coefficients, 516  
Cytochrome P-448, *n*-octylamine difference spectra,  
  in rat and mice, 602  
Cytochrome P-450  
  binding of barbiturates to, 663  
  effect of centrally active drugs on, 669  
  extinction coefficients, 516  
  heme degradation, role in pentobarbital and acet-  
  anilide metabolism, 766  
  *n*-octylamine difference spectra in rat and mice, 602  
  solubilization, 516  
  
Deacetylcephalothin, ion-pair extraction and liquid  
  chromatography, in man, 659  
Dialkyl esters, methotrexate and 3',5'-dichloro-  
  methotrexate, 580  
Diazepam, effect, on liver microsomal enzymes, 669  
3',5'-Dichloromethotrexate  
  dialkyl esters, 580  
  7-hydroxy-, 580  
2,4-Dichloro-6-phenylphenoxyethylamine, metabo-  
  lism, relationship with activity as mono-oxy-  
  genase inhibitor, 628  
<sup>14</sup>C-Dicumarol, biliary excretion, in rat, 523  
<sup>3</sup>H-Digitoxin, excretion, effect of spironolactone on,  
  in rat, 590  
Dihydrofolate reductase, synthesis and interaction of  
  dialkyl esters with, 580  
4-[3-(Dimethylamino)propyl]-3,4-dihydro-2-(1-hy-  
  droxyethyl)-3-phenyl-2H-1,4-benzothiazine,  
  metabolism, in rat, dog, and monkey, 619  
Diphenylhydantoin  
  effect, on liver microsomal enzymes, 669  
  metabolism, 711  
Dopamine-<sup>14</sup>C, metabolism, species differences, 691  
  
Editorial, 487  
Elimination rate, ethanol, in chimpanzee and mon-  
  key, 634  
Enantiomers  
  metabolism, microsomal, 642  
  substrate binding, 642  
Ethanol  
  effect



- on ethanol elimination rate in chimpanzee and rhesus monkey, 634  
on liver microsomal enzymes, 669  
elimination rate, in chimpanzee and rhesus monkey, 634
- Ethosuximide, metabolism, in rat and man, 569
- 2-Ethyl-2-methylsuccinimide, metabolism, in rat and man, 569
- Ethylmorphine N-demethylase, effect of centrally active drugs on, 669
- Excretion, fecal, of digitoxin metabolites in rat, 590
- cis*-5-Fluoro-2-methyl-1-[*p*-(methylsulfinyl)-benzylidene]-indene-3-acetic acid, disposition and metabolism, species differences, 721
- Glucuronides  
identification by mass spectrometry in rat bile, 489  
monohydroxyethosuximide, 569
- Griseofulvin  
effect, on O-demethylation of griseofulvin, in rat and mice, 611  
metabolism, in rat and mice, 611
- Hexobarbital hydroxylation, 663  
in liver microsomes, 760
- 18-Homoestriol metabolic disposition, species differences, 537
- Hydroxycamphors, oxidation, 543
- Hydroxylation  
barbiturates, 663  
ring, lack, in metabolism of probenecid, 742  
warfarin, in guinea pig, 704
- 2-Hydroxynicotinic acid, biotransformation, 557
- Hypoprothrombinemia, produced by warfarin and metabolites, 704
- Inhibitors, mono-oxygenase, 628
- Ion-pair extraction, of cephalothin and deacetylcephalothin, in man, 659
- 1-(2-Isopropylphenyl)imidazole, as inhibitor of drug metabolism, 775
- L1210 leukemia cells, metabolism of O<sup>2</sup>,2'-cyclocytidine in, 752
- Lipid peroxidation, role, in pentobarbital and acetanilide metabolism, 766
- Liver microsomes  
O-demethylation of griseofulvin by, in rat and mice, 611  
enzymes, effects of various drugs on, 669  
extinction coefficients of hemoproteins in, 516  
hydroxylation of barbiturates by, 663  
metabolism  
kinetics, 642  
of drugs, modifiers, 775  
of pentobarbital and acetanilide, rate, 766  
of SQ 11,579, in rat, dog, and monkey, 619  
oxidation of hexobarbital by, 760
- Mass spectrometry  
chemical ionization, 506  
electron impact, 506  
identification of glucuronides in rat bile by, 489
- Mass spectroscopy, characterization of 1-methyl-(2,6-xylyloxy)ethylamine metabolites by, 506
- Meprobamate, effect, on liver microsomal enzymes, 669
- Methotrexate  
dialkyl esters, 580  
7-hydroxy-, 580
- N-Methylation, pathway for oxprenolol metabolism, in dog, 565
- 3-Methylcholanthrene, effects  
on O-demethylation of griseofulvin in rat and mice, 611  
on *n*-octylamine-cytochrome P-450 difference spectra interaction, 602
- 1-Methyl-(2,6-xylyloxy)ethylamine metabolites, characterization, 506
- Monohydroxyethosuximide metabolites, in rat and man, 569
- Nuclear magnetic resonance  
<sup>13</sup>C and <sup>1</sup>H, characterization of 1-methyl-(2,6-xylyloxy)ethylamine metabolites by, 506  
Fourier transform, 506
- n*-Octylamine, difference spectra of cytochromes P-450 and P-448, in rat and mice, 602
- Oxprenolol, metabolism, in dog, 565
- Pentobarbital  
hydroxylation, 663  
metabolic rate, 766
- Permethylation, rat bile, identification of metabolites in, 489
- Phenobarbital, effects  
on O-demethylation of griseofulvin in rat and mice, 611  
on liver microsomal enzymes, 669
- Probenecid, metabolites and analogs, 742
- Propranolol, disposition, 679, 687
- Quingestanol acetate, disposition, in rat, 530
- N-Riboside, formation *in vivo*, 557
- Ribosyl-6-mercaptopurine, metabolism and disposition, 645
- Seclazone, biotransformation, binding, and disappearance, in rat and dog, 737
- SKF 525-A, effect, on propranolol disposition, 679
- Spiroonolactone, effect, on <sup>3</sup>H-digitoxin excretion in rat, 590
- SQ 11,579, metabolism, in rat, dog, and monkey, 619
- Stereochemistry, effect, on drug metabolism, 642
- Steroids, disposition, in rat, 530

- Terpenoids, metabolism, mammalian, 543  
Tetrahydrofurfuryl mercaptan, metabolite of thiamine  
tetrahydrofurfuryl disulfide, 698  
Tetralin  
metabolism, in man, 577  
toxicity, in man, 577  
Thiamine, plasma and tissue levels, 698  
Thiamine tetrahydrofurfuryl disulfide, absorption and  
disposition, in dog and man, 698  
Thiopurines, metabolism and disposition, 645  
Warfarin, metabolism, in guinea pig, 704